GlassScriptPhysician profile
Craig W Davis
NPI 1861643330
$12,864.47
in general payments reported to CMS, 2019-2025
33 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $6,396 · 2021: $526 · 2022: $1,029 · 2023: $884 · 2024: $523 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,668.85 | 2020 | |
| Medtronic, INC. | $2,141.14 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Abbott Laboratories | $715.00 | 2019-2025 | Eterna, Proclaim |
| Boston Scientific Corporation | $662.02 | 2019-2025 | General - Pain Management, Intracept, Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $520.92 | 2019-2020 | |
| Globus Medical, INC. | $506.59 | 2025 | Senza |
| Pacira Pharmaceuticals Incorporated | $393.00 | 2019 | |
| Nevro Corp. | $343.43 | 2019-2024 | Senza |
| Stimwave Technologies Incorporated | $260.88 | 2019-2022 | |
| Pfizer INC. | $215.04 | 2019-2025 | |
| Biotronik Nro, INC. | $202.89 | 2025 | Prospera |
| Abbvie INC. | $186.70 | 2021-2024 | Qulipta |
| Relievant Medsystems, INC. | $180.75 | 2021-2023 | Intracept |
| Allergan, INC. | $117.56 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $104.58 | 2022-2024 | Belbuca |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $94.85 | 2022-2024 | Nalu Neurostimulation System |
| Novartis Pharmaceuticals Corporation | $82.55 | 2019 | |
| Averitas Pharma INC. | $74.69 | 2023-2024 | Qutenza |
| Janssen Biotech, INC. | $73.84 | 2025 | Tremfya |
| Spr Therapeutics, INC | $49.78 | 2022 | |
| Lundbeck LLC | $49.05 | 2022-2024 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.77 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $24.94 | 2019-2022 | |
| Avanos Medical | $21.36 | 2025 | Generator |
| Biohaven Pharmaceuticals, INC. | $20.93 | 2021 | |
| Genzyme Corporation | $20.25 | 2022 | |
| Redhill Biopharma INC. | $17.95 | 2020 | |
| Amgen INC. | $16.59 | 2019 | |
| Si-Bone, INC. | $16.24 | 2021 | |
| Grt US Holding, INC. | $15.20 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.81 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.